BPG is committed to discovery and dissemination of knowledge
Prospective Study
Copyright: ©Author(s) 2026.
World J Psychiatry. Nov 19, 2026; 16(11): 122105
Published online Nov 19, 2026. doi: 10.5498/wjp.122105
Table 1 Comparison of baseline data between the two groups of patients, mean ± SD/n (%)

Control group (n = 60)
Observation group (n = 60)
t/χ2
P value
Age (years)53.23 ± 11.3151.69 ± 10.700.7660.445
Gender0.3150.575
    Male35 (58.33)38 (63.33)
    Female25 (41.67)22 (36.67)
BMI (kg/m2)23.15 ± 1.3723.20 ± 1.40-0.1940.846
Disease course (months)5.16 ± 1.055.14 ± 1.040.0780.938
Lesion location0.1340.714
    Left31 (51.67)33 (55.00)
    Right29 (48.33)27 (45.00)
Table 2 Comparison of treatment scores between the two groups of patients, mean ± SD
SFGS score (scores)
Before treatment
After treatment
Control group (n = 60)35.02 ± 6.9967.12 ± 6.62
Observation group (n = 60)34.30 ± 8.3384.20 ± 7.59
t0.511-13.140
P value0.611< 0.001
Table 3 Comparison of anxiety and depression symptom scores between the two groups of patients, mean ± SD
SAS score (scores)
SDS score (scores)
Before treatment
After treatment
Before treatment
After treatment
Control group (n = 60)58.80 ± 3.9144.32 ± 1.9959.07 ± 2.3644.37 ± 2.46
Observation group (n = 60)58.32 ± 3.4234.90 ± 2.0159.13 ± 2.5334.22 ± 2.10
t0.72125.833-0.14924.330
P value0.472< 0.0010.882< 0.001
Table 4 Comparison of clinical efficacy between the two groups of patients, n (%)

Number of examples
Get well
Effective
Efficient
Invalid
Overall efficiency
Control group6012 (20.00)18 (30.00)17 (28.33)13 (21.67)47 (78.33)
Observation group6018 (30.00)22 (36.67)15 (25.00)5 (8.33)55 (91.67)
χ24.183
P value0.041


Write to the Help Desk